| Changes in weight loss‐related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin S Grandy, M Hashemi, AM Langkilde, S Parikh, CD Sjöström Diabetes, Obesity and Metabolism 16 (7), 645-650, 2014 | 49 | 2014 |
| Dapagliflozin‐induced weight loss affects 24‐week glycated haemoglobin and blood pressure levels CD Sjöström, M Hashemi, J Sugg, A Ptaszynska, E Johnsson Diabetes, Obesity and Metabolism 17 (8), 809-812, 2015 | 48 | 2015 |
| A phase 2a, double-blind, placebo-controlled randomized trial of inhaled TLR9 agonist AZD1419 in asthma I Psallidas, V Backer, P Kuna, R Palmér, S Necander, M Aurell, ... American Journal of Respiratory and Critical Care Medicine 203 (3), 296-306, 2021 | 22 | 2021 |
| Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials TH Myrbäck, S Prothon, K Edman, J Leander, M Hashemi, M Dearman, ... The Lancet Rheumatology 2 (1), e31-e41, 2020 | 16 | 2020 |
| Characterisation of pharmacokinetics, safety and tolerability in a first‐in‐human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway … MW Sadiq, S Asimus, MG Belvisi, W Brailsford, R Fransson, R Fuhr, ... British Journal of Clinical Pharmacology 88 (1), 260-270, 2022 | 10 | 2022 |
| Dapagliflozin-induced weight loss impacts 24 week HbA (1c) and blood pressure levels CD Sjostrom, M Hashemi, J Sugg, A Ptaszynska, E Johnsson Diabetologia 56, S81-S81, 2013 | 3 | 2013 |
| Combined HbA1c and weight reduction is achieved more frequently with add-on dapagliflozin than add-on glipizide in patients with type 2 diabetes inadequately controlled on … K Rohwedder, MA Nauck, S Duran-Garcia, M Hashemi, SJ Parikh DIABETES 62, A60-A61, 2013 | 2 | 2013 |
| A Phase 2a randomized, double-blind, placebo-controlled trial with withdrawal design of AZD1419, a Toll-9 agonist in adults with eosinophilic, moderate to severe asthma I Psallidas, V Backer, P Kuna, L Molnar, M Aurell, K Korsback, R Palmer, ... B21. SEVERE ASTHMA: CLINICAL AND MECHANISTIC STUDIES, A7361-A7361, 2019 | 1 | 2019 |
| Early Phase Trial Study Design with an Efficacy Biomarker Threshold M HASHEMI, G DESACHY PSI 2021, 2021 | | 2021 |
| Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis R Palmér, J Almquist, M Hashemi, Z Taib, S Necander, K Korsback, ... European Respiratory Journal 56 (suppl 64), 2020 | | 2020 |
| Correlation between clinic and remote FEV1 and FeNO measurements; post hoc analysis of the INCONTRO study S Necander, M Hashemi, Z Taib, R Palmér, K Korsback, M Aurell, ... European Respiratory Journal 56 (suppl 64), 2020 | | 2020 |
| Application of machine learning algorithms to predict loss of asthma control: A post-hoc analysis of INCONTRO study S Necander, A Teixeira, V Chaudhuri, M Hashemi, R Pálmer, K Korsback, ... European Respiratory Journal 56 (suppl 64), 2020 | | 2020 |
| SAT0251 Selective glucocorticoid receptor modulator shows potent anti-inflammatory effect with improved metabolic profile in a phase i study supported by in vitro data TH Myrbäck, S Prothon, M Dearman, G Edenro, J Leander, M Hashemi, ... Annals of the Rheumatic Diseases 77 (Suppl 2), 987-987, 2018 | | 2018 |
| Administrative Interim Analyses: the more the merrier? M Hashemi, Z Taib The 26th Nordic conference in Mathematical Statistics - Copenhagen (27-30 …, 2016 | | 2016 |
| Gleichzeitige HbA1c-und Gewichtsverringerung häufiger unter Dapagliflozin als unter Glipizid bei einer Zusatztherapie bei Typ-2-Diabetikern mit unzureichender … K Rohwedder, M Nauck, S Durán-Garcia, M Hashemi, SJ Parikh Diabetologie und Stoffwechsel 9 (S 01), P139, 2014 | | 2014 |
| Gewichtsverlust durch Dapagliflozin beeinflusst HbA1c-Spiegel und Blutdruckwerte nach 24 Wochen D Sjöström, M Hashemi, J Sugg, A Ptasynska, E Johnsson, K Rohwedder Diabetologie und Stoffwechsel 9 (S 01), P134, 2014 | | 2014 |
| Dapagliflozin-induced weight loss impacts 24 week HbA1c and blood pressure levels EJ David Sjöström, Mahdi Hashemi, Jennifer Sugg, Agata Ptaszynska 49th European Association for the Study of Diabetes (EASD), Barcelona, 2013 | | 2013 |
| Combined HbA (1c) and weight reduction is more frequent with dapagliflozin vs glipizide add-on treatment in patients with type 2 diabetes inadequately controlled on metformin K Rohwedder, MA Nauck, S Duran-Garcia, M Hashemi, SJ Parikh DIABETOLOGIA 56, S376-S376, 2013 | | 2013 |
